^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Source:
Title:

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Published date:
08/25/2022
Excerpt:
The results of EMPOWER-Lung 3 demonstrate that cemiplimab in combination with platinum-doublet chemotherapy is a potential first-line treatment option for patients with advanced squamous and non-squamous NSCLC, regardless of PD-L1 expression level and without EGFR, ALK or ROS1 aberrations.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1038/s41591-022-01977-y